Navigation Links
InterMune to Present at Canaccord Adams Conference
Date:8/7/2009

BRISBANE, Calif., Aug. 7 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Canaccord Adams 29th Annual Global Growth Conference in Boston on August 12, 2009 at 10:30 a.m. EDT.

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with IPF (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) expected to enter Phase 2b in August of 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
2. InterMune to Release Second Quarter Financial Results on August 6
3. InterMune to Present at Goldman Sachs Healthcare Conference
4. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
5. InterMune to Release First Quarter Financial Results on April 30
6. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
7. InterMune to Present at Canaccord Adams Hepatitis C Conference
8. InterMune to Present at Citis 4th Annual Biotech Day
9. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
10. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
11. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 2014 US demand to rise 3.9% annually ... is forecast to rise 3.9 percent per year to ... projected to increase 1.3 percent per year to 1.5 ... in construction expenditures will support demand for biocides in ... growth in consumer spending and manufacturing output will support ...
(Date:9/22/2014)... Invisible Sentinel Inc., a life-sciences company ... beverage industries, announced today that its first-in-class Veriflow® ... agreement by Enartis, a global provider of specialty ... Group company headquartered in Trecate, Italy, will distribute ... global markets for their own in-winery use in ...
(Date:9/22/2014)... LONDON , September 22, 2014 ... ended on a mixed note as the Dow Jones ... NASDAQ Composite closed at 4,579.79, down 0.30%. The S&P ... the trading session, six out of ten sectors finished ... Sector Index ended the day at 751.48, up 0.10%, ...
(Date:9/21/2014)... first time, scientists have discovered how to produce ultra-thin ... stiffness greater than that of today,s strongest nanotubes and ... team led by John V. Badding, a professor of ... the 21 September 2014 issue of the journal ... view, our discovery is intriguing because the threads we ...
Breaking Biology Technology:US Biocides Market 2US Biocides Market 3Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 2Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5Smallest possible diamonds form ultra-thin nanothreads 2Smallest possible diamonds form ultra-thin nanothreads 3Smallest possible diamonds form ultra-thin nanothreads 4
... - From less than 1 million to 600 ... growth in the past 10 years. , ,From the ... job, providing better tools for finding, filtering and presenting ... decade on the Web and also looking forward to ...
... Madison, Wis. - Stratatech Corporation , a UW ... from the National Institute on Aging, for the development of ... wounds such as diabetic, venous stasis and pressure ulcers, which ... estimated that in the United States alone, millions of people ...
... Madison, Wis. Pierce Biotechnology , a ... BioSurfaces of Madison, Wis., to distribute GenTel's trademarked ... use of GenTel technology in developing new protein arrays ... specifically designed for protein-array applications, including the profiling of ...
Cached Biology Technology:Internet Scout celebrates 10 years on web, eyes new project launch 2
(Date:9/22/2014)... New Haven, Conn. Yale University researchers are studying ... pulmonary fibrosis, a respiratory disease in which scars develop ... treatment uses a microRNA mimic, miR-29, which is delivered ... only blocked pulmonary fibrosis, it reversed fibrosis after ... in the journal EMBO Molecular Medicine . , ...
(Date:9/22/2014)... molecular cog in a plant,s biological clock one ... on temperature. , Transcription factors, or genetic switches, drive ... such as light, rain, soil quality, or even animals ... has isolated one, called FBH1, that reacts to temperature ... while in keeping it on a consistent track. , ...
(Date:9/22/2014)... of the fires captured in this image burn in Khabarovsk ... Okhotsk. Dozens of red hotspots, accompanied by plumes of smoke ... grey, blows to the east towards the Sea of Okhotsk. ... of this area, swampy forest inhabit the central depression, and ... While large wildfires are common in Russia in the summer, ...
Breaking Biology News(10 mins):Reversing the effects of pulmonary fibrosis 2Genetic switch regulates a plant's internal clock based on temperature 2
... Recognizes Leadership in Technology and Innovation in Global ... LMT ) has been named the ... Frost and Sullivan, recognizing the Corporation,s leadership in ... of customers. Frost and Sullivan based the award ...
... The Centre for Genomic Regulation (CRG) in Barcelona, Spain ... by Genomatix Software GmbH. , GGA comprises purpose built ... software providing a complete solution for the analysis of ... genome. "In regards to the machine, I love ...
... 4, 2009 The incidence of pneumothorax (PTX), or collapsed ... has been reported to range from 13 50 percent, ... In people, PTX is reported to be the most preventable ... ultrasound has been infrequently used as a non-invasive, point-of-care imaging ...
Cached Biology News:Lockheed Martin Named Biometrics 'Company of the Year' by Frost and Sullivan 2CRG buys Genomatix' Next Generation Sequencing analysis solution 2Novel veterinary procedure detecting life-threatening injuries touted 2
Use the DUALmembrane kit 3 to carry out DUALmembrane interaction analysis and cDNA library screening to characterize interactions between integral membrane proteins and to identify novel interaction ...
Human Serum FDA Licensed US Donor Centers Sterile / Non-sterile: Sterile Filtered to 0.2 micron Information: Extensive Viral Testing ...
Normal human AB serum, pooled...
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
Biology Products: